A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors. 177Lu-edotreotide shows potential to extend ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Scientists at the University of Michigan Rogel Cancer Center have found a promising new way to fight one of the most ...

Market advancements are driven by rising incidences of neuroendocrine tumors, improved diagnostics, and targeted therapies. Key players like Novartis AG and Pfizer Inc. are investing in innovative ...

The study, published in the Journal of Clinical Investigation, reveals that pyrvinium pamoate—a drug approved in the 1950s to ...

Neuroendocrine tumors (NETs) are rare, often slow-growing, tumors that begin in neuroendocrine cells and can occur anywhere in the body. The most common sites for NETs to occur are the digestive ...

(MENAFN- GlobeNewsWire - Nasdaq) Market advancements are driven by rising incidences of neuroendocrine tumors, improved diagnostics, and targeted therapies. Key players like Novartis AG and Pfizer ...

GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- The HealthWell Foundation ®, an independent non-profit charitable organization that provides financial assistance for underinsured Americans has ...